Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study.

ABSTRACT:

Objectives

To compare the risk of incident uveitis among patients with axial spondyloarthritis initiating treatment with Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).

Methods

We conducted an emulated target trial using real-world electronic health records from the TriNetX US Collaborative Network. Adults with ankylosing spondylitis (AS), psoriasis (PsO), or psoriatic arthritis (PsA) who newly initiated a JAKi or a TNFi between January 1, 2016, and December 31, 2023, were identified. Patients were stratified into JAKi and TNFi cohorts based on initial treatment exposure. Propensity score matching (1:1) was performed to balance baseline demographics, comorbidities, prior medication use, and laboratory values. Cox proportional hazards models wer

SUBMITTER: Bai WH 

PROVIDER: S-EPMC12592076 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature